Eisai Announces Results Of Phase III Study Of Dacogen(R) (Decitabine) For Injection In Acute Myeloid Leukemia (AML)
Article Date: 04 Jul 2010 - 0:00 PDT
Eisai Inc. announced preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults. ...
INDIANAPOLIS -- The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.
Celgene's Vidaza to Retain Proprietary Clinical Gold Standard Status for the Treatment of Myelodysplastic Syndromes
TradingMarkets.com
Posted on: Wed, 28 Apr 2010 00:59:22 EDT
Apr 28, 2010 (Close-Up Media via COMTEX)
Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, finds that Celgene's Vidaza (azacitidine) (seven-day dosing) will retain Decision Resources' proprietary clinical gold standard status through 2013...
WASHINGTON, DC -- April 5, 2010 -- A genetic treatment for leukaemia may improve remission and survival outcomes in elderly patients compared to existing remedies such as intensive chemotherapy, according to a report published in the latest issue of Proceedings of the National Academy of Sciences (PNAS).
Carlo Croce, MD, Department of Immunology and Medical Genetics, Ohio State University, Columbus, Ohio, and colleagues administered decitabine,...
Updated NCCN Guidelines for AML Include Risk Stratification to Assist in
Treatment Selection
The National Comprehensive Cancer Network (NCCN) recently updated the NCCN Guidelines for Acute Myeloid Leukemia (AML), the most common acute leukemia affecting adults. Noteworthy updates include the incorporation of risk stratification based on white blood cell count, the alternative to use cord blood in allogeneic...
